-
公开(公告)号:US10987033B2
公开(公告)日:2021-04-27
申请号:US15775254
申请日:2016-11-11
Applicant: MicroOptx Inc.
Inventor: Roy Christian Martin , Christopher Clark Pulling , Christopher Thomas Martin , J. David Brown
IPC: A61B5/1455 , A61B5/145 , A61B5/1459 , A61B5/00
Abstract: A method for monitoring glucose concentration in aqueous humor can include inserting an implantable device into an eye and determining glucose concentration as a function of glucose sensed at the implantable device. The method can optionally include optically detecting glucose concentration as a function of polarimetry and/or fluorescence. A system for monitoring glucose concentration can include devices described herein.
-
公开(公告)号:US20180333085A1
公开(公告)日:2018-11-22
申请号:US15775254
申请日:2016-11-11
Applicant: MicroOptx Inc.
Inventor: Roy Christian Martin , Christopher Clark Pulling , Christopher Thomas Martin , J. David Brown
IPC: A61B5/145 , A61B5/1459 , A61B5/00
CPC classification number: A61B5/14532 , A61B5/14507 , A61B5/1455 , A61B5/1459 , A61B5/6821 , A61B5/686
Abstract: A method for monitoring glucose concentration in aqueous humor can include inserting an implantable device into an eye and determining glucose concentration as a function of glucose sensed at the implantable device. The method can optionally include optically detecting glucose concentration as a function of polarimetry and/or fluorescence. A system for monitoring glucose concentration can include devices described herein.
-
公开(公告)号:US20180280195A1
公开(公告)日:2018-10-04
申请号:US15764634
申请日:2016-09-30
Applicant: MicroOptx Inc.
Inventor: J. David Brown
Abstract: Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described.
-
公开(公告)号:US20170367888A1
公开(公告)日:2017-12-28
申请号:US15540904
申请日:2015-12-30
Applicant: MicroOptx Inc.
Inventor: J. David BROWN
CPC classification number: A61F9/00781 , A61F2220/0016 , A61F2220/0033 , A61F2250/006 , A61L27/18 , A61L27/28
Abstract: Devices can be implanted in an eye to treat glaucoma. The devices described herein include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. By the strategic selection of particular materials of construction, and/or by controlling the configuration and size of the lumen, in some embodiments, the device is a filterless construct. In some embodiments, a filter is included. The glaucoma treatment devices as provided herein are designed to prevent bacterial ingress and to provide the required level of outflow resistance to achieve a desired intraocular pressure. Methods of treating glaucoma wherein the device is implanted in the sclera of an afflicted eye are also described.
-
公开(公告)号:US11291391B2
公开(公告)日:2022-04-05
申请号:US16209010
申请日:2018-12-04
Applicant: MicroOptx Inc.
Inventor: Edward Aaron Cohen , Roy Christian Martin
Abstract: Monitoring glucose concentration in aqueous humor can include inserting an implantable device into an eye and determining glucose concentration as a function of glucose sensed at the implantable device. In some implantable device embodiments, the device includes a polymer layer comprising a material that changes volume in response to varying glucose concentrations of the aqueous humor. A pressure sensor in the device can detect the changes in volume. In some implantable device embodiments, the device includes electrodes for determining the glucose concentration.
-
公开(公告)号:US20210220172A1
公开(公告)日:2021-07-22
申请号:US17223890
申请日:2021-04-06
Applicant: MicroOptx Inc.
Inventor: J. David Brown
Abstract: Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described.
-
公开(公告)号:US11039954B2
公开(公告)日:2021-06-22
申请号:US16360777
申请日:2019-03-21
Applicant: MicroOptx Inc.
Inventor: Edward Aaron Cohen , Daniel Charles Voce
Abstract: An implantable ocular drug delivery system can include inserting an implantable device into an eye, where the device contains therapeutics intended to be released for local or systemic effects. In some implantable device embodiments, the device includes a microchannel intended to reduce intraocular pressure. In some implantable device embodiments, the device includes a microchannel intended to treat dry eye.
-
公开(公告)号:US10980667B2
公开(公告)日:2021-04-20
申请号:US15764634
申请日:2016-09-30
Applicant: MicroOptx Inc.
Inventor: J. David Brown
Abstract: Devices can be implanted in an eye to treat a dry eye condition. The devices include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. In some embodiments, the device is filterless. In some embodiments, a filter is included. The dry eye treatment devices provided herein prevent bacterial ingress, provide outflow resistance to retain a normal intraocular pressure, and provide moisture (e.g., aqueous humor) to an otherwise dry eye. Methods of treating a dry eye condition wherein the device is implanted in the sclera of an afflicted eye are also described.
-
公开(公告)号:US20200315846A1
公开(公告)日:2020-10-08
申请号:US16910867
申请日:2020-06-24
Applicant: MicroOptx Inc.
Inventor: J. David Brown
Abstract: Devices can be implanted in an eye to treat glaucoma. The devices described herein include a body defining a lumen and having first and second ends and external and lumenal surfaces. The body has a length sufficient to provide fluid communication between the anterior chamber and tear film of the eye through the lumen when the device is implanted in the sclera. By the strategic selection of particular materials of construction, and/or by controlling the configuration and size of the lumen, in some embodiments, the device is a filterless construct. In some embodiments, a filter is included. The glaucoma treatment devices as provided herein are designed to prevent bacterial ingress and to provide the required level of outflow resistance to achieve a desired intraocular pressure. Methods of treating glaucoma wherein the device is implanted in the sclera of an afflicted eye are also described.
-
公开(公告)号:US20210219878A1
公开(公告)日:2021-07-22
申请号:US17220791
申请日:2021-04-01
Applicant: MicroOptx Inc.
Inventor: Roy Christian Martin , Christopher Clark Pulling , Christopher Thomas Martin , J. David Brown
IPC: A61B5/145 , A61B5/1459 , A61B5/1455 , A61B5/00
Abstract: A method for monitoring glucose concentration in aqueous humor can include inserting an implantable device into an eye and determining glucose concentration as a function of glucose sensed at the implantable device. The method can optionally include optically detecting glucose concentration as a function of polarimetry and/or fluorescence. A system for monitoring glucose concentration can include devices described herein.
-
-
-
-
-
-
-
-
-